Denifanstat's 52-Week Acne Data: 57% IGA Success and AURORA Screening Set for October
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Positive 52-week OLE data for denifanstat in acne were reported, and AURORA Phase 3 screening is confirmed to begin in October 2026.
Key Events · Product Development and Regulatory · SGMT
-
52-Week OLE Data Shows Durable Efficacy
At 52 weeks in the ASC40-304 open-label extension, denifanstat achieved 57% IGA success, 72% total lesion reduction, and 77% inflammatory lesion reduction, with no drug-related serious adverse events.
-
AURORA Screening Starts October 2026
Patient screening for the U.S. Phase 3 AURORA trial is expected to begin in October 2026, with first patient enrollment shortly thereafter — a concrete timeline for the ~800-patient study.
-
Safety Profile Remains Clean
Over 52 weeks, only dry skin (7.1%) and dry eye (5.9%) exceeded 5% incidence among treatment-related adverse events; no permanent discontinuations due to adverse events.
-
ATM Offering Terminated
Effective September 30, 2026, Sagimet suspended and terminated its ATM prospectus supplement; no shares were sold under the Sales Agreement with Leerink Partners.
Analysis · SGMT · Life Sciences
The 52-week open-label extension data from Ascletis' Phase 3 trial strengthens denifanstat's clinical profile ahead of Sagimet's own U.S. Phase 3 AURORA trial. Patients showed progressive improvement with longer treatment — 57% IGA success, 72% total lesion reduction, and 77% inflammatory lesion reduction — with no drug-related serious adverse events and no permanent discontinuations. Critically, the company confirmed patient screening for AURORA begins in October 2026, converting a previously vague '2H 2026' timeline into a concrete near-term milestone. This de-risks the acne program and positions denifanstat as a potential first-in-class oral therapy for a 10-million-patient U.S. market.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.6% of the 978 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $9.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.6M. The 52-week trading range was $4.50 to $11.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.